

IL-17A Protein, Cynomolgus, Recombinant (His)

General Information

Synonyms:	CTLA-8;CTLA8;IL17A;IL-17;IL-17A;Cytotoxic T-Lymphocyte-Associated Antigen 8;Interleukin-17A;IL17
Protein Construction:	Gly24--Ala155
Species:	Cynomolgus
Expression Host:	HEK293 Cells
Accession:	A0A2K5TTB0
Molecular Weight:	15-25 KDa (reducing condition)
AA Sequence:	Gly24-Ala155

QC Testing

Biological Activity:	1. Loaded Biotinylated Human IL-17RA-Fc on Pro A Biosensor, can bind Cynomolgus IL-17A-His with an affinity constant of 0.33 nM as determined in BLI assay. (Regularly tested) 2. Immobilized Cynomolgus IL-17A-His at 2µg/ml (100 µl/well) can bind Anti-Human IL-17A mAb. The ED50 of Anti-Human IL-17A mAb is 0.128 ug/ml. (Regularly tested)
Purity:	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Endotoxin:	< 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS, pH 7.4.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients

A DRUG SCREENING EXPERT

with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481